关键信息
-
基因名
CYP2A13
- 应用
-
别名
(CYPIIA13)
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & C- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q16696
-
表达区间
1-494aa
-
分子量
64.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CYP2A13, a member of the cytochrome P450 family, is an important enzyme that primarily catalyzes the metabolism of nicotine and various other xenobiotics. Recent research has shown that CYP2A13 is predominantly expressed in human respiratory tissues and plays a significant role in the activation of procarcinogens present in tobacco smoke, contributing to lung cancer risk associated with smoking. Studies have indicated that genetic polymorphisms in the CYP2A13 gene may influence individual susceptibility to tobacco-related cancers. The full understanding of CYP2A13’s structure, function, and interactions with various substrates can provide insights into its role in drug metabolism, toxicology, and carcinogenesis. The recombinant expression of CYP2A13 in various heterologous systems, such as bacterial or yeast cultures, has facilitated the characterization of this enzyme's kinetic properties and substrate specificity. Through the production of CYP2A13 recombinant protein, researchers aim to elucidate its mechanisms of action, explore potential inhibitors, and investigate its pharmacogenomic implications in personalized medicine. Continued exploration of CYP2A13 is crucial for developing strategies for cancer prevention and for understanding the complexities of drug metabolites within human health and disease contexts.
